Overview

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk. Newer anti-diabetic agents - exenatide and saxagliptin - impact lipid metabolism. These medications will be studied for their effect in reducing both postprandial lipid levels and arterial dysfunction.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborator:
The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston
Treatments:
Exenatide
Hypoglycemic Agents
Saxagliptin